Abbott Laboratories (NYSE:ABT) reported new FreeDM2 trial results on its FreeStyle Libre continuous glucose monitoring system for people with Type 2 diabetes using basal insulin. The company also ...

The study was carried out at 24 clinical sites across the UK and included 303 participants.

About 3 million FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors manufactured by Abbott were recalled in November, because they might give wrong readings.

Abbott (NYSE: ABT), a global healthcare leader, today announced results from the FreeDM2 randomized controlled trial (RCT) showing that people using FreeStyle Libre continuous glucose monitoring (CGM) ...

Key collaborations enable Abbott to increase its global presence and accessibility to patients who haven't used CGMs before, potentially resulting in a 15% CAGR in FreeStyle Libre sales by 2028. With ...

Abbott recalled certain sensors used in its FreeStyle Libre 3 and FreeStyle Libre 3 Plus systems, warning they could produce ...

Add Yahoo as a preferred source to see more of our stories on Google. FreeStyle Libre 3 sensor by Abbott Image by Adobe Medical device giant Abbott announced on Sunday that it is recalling ...

Traditional food logging apps offer feedback after the fact—Libre Assist 1 offers help in-the-moment to inform mealtime decisions before every bite Libre Assist 1 leverages AI to predict how food ...

Following a major sales bump in the second quarter of 2019, Abbott Laboratories is planning to significantly ramp up manufacturing for its FreeStyle Libre continuous glucose monitoring system, the ...

ABBOTT PARK, Ill., Jan. 5, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), a leading healthcare company, today unveiled Libre Assist,1 a groundbreaking feature within the Libre app5 designed to help the ...